Top 10 Pharma Drug Discovery and Delivery Capital Raises in the U.S. – March 16th – 31st, 2025

Top 10 Pharma Drug Discovery and Delivery Capital Raises in the U.S. – March 16th – 31st, 2025

Several interesting transactions closed in the Pharma Drug Discovery and Delivery sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.

PIPE

    1. Cyclacel Pharmaceuticals Inc., a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases, received $1 million of development capital from investors on March 21, 2025, through a private placement.
    2. Plus Therapeutics Inc., a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases, received $18.2 million of development capital from investors on March 27, 2025, through a private placement.

Merger/Acquisition and Corporate

    1. Antibe Therapeutics Inc., leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions, was acquired by Taro Pharmaceutical Industries (NYS: TARO), a subsidiary of Sun Pharmaceutical Industries (NSE: SUNPHARMA), for CAD 4.5 million on March 17, 2025.
    2. Genetic Networks, developer of a drug asset development platform intended to integrate a genome-wide functional assay of drug activity, was acquired by Fifty 1 Labs for $10 million on March 20, 2025.

Early Stage VC

    1. Ampersand Biomedicines, developer of medicines and body therapeutics designed to act at the site of disease, raised $65 million of Series B venture funding lead by Flagship Pioneering and joined by Eli Lilly and Company and other investors on March 19, 2025, putting the company’s pre-money valuation at $273 million.
    2. Hillstar Bio, developer of autoimmune drugs intended to address unmet medical needs, raised $66.5 million of Series A venture funding in a deal led by Novo Holdings, Hummingbird Bioscience and LifeArc Ventures on March 25, 2025, putting the company’s pre-money valuation at $38.5 million.

Later Stage VC

    1. Aveta Biomics, developer of nature-inspired drugs designed to provide a durable response to cancer patients, raised $4.46 million of venture funding from investors on March 19, 2025.
    2.  Cimeio Therapeutics, developer of immunotherapy technology designed to treat leukemic tumors, autoimmune diseases, bone marrow transplants and stem cell replacement, raised $2.1 million of venture funding from investors on March 21, 2025.

Seed Round

    1. Topaz Biosciences, developer of enzyme-based ingredients designed for rebalancing the skin microbiome, raised $1.44 million through the combination of Seed-1, Seed-2 and Seed-3 funding from investors on March 18, 2025, putting the company’s pre-money valuation at $8.57 million.
    2. ViroMissile, developer of medical cures designed to provide treatment for cancer, raised $100,000 of seed funding from investors on March 19, 2025.

 

#castleplacement #capitalraising #privateequity #venturecapital #investment #pharmadrugdiscoveryanddelivery

Please contact me if you have any questions or would like to discuss your capital raise:

Email: druddy@castleplacement.com

(C) (406) 868-3218

Send us a message:

Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.

CONTACT US

Hi. We're not around right now. But you can send us an email and we'll get back to you, asap.

Thanks, Ken

Ken Margolis | Managing Partner Castle Placement
1460 Broadway Street
New York, New York 10036
(212) 418-1180
kmargolis@castleplacement.com

Sending

Log in with your credentials

Forgot your details?